Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIUDELLA vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MIUDELLA (everolimus) is an m TOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the m TOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Advanced HR+, HER2- breast cancer in postmenopausal women (with exemestane after failure of letrozole or anastrozole),Progressive neuroendocrine tumors of pancreatic origin (PNET) in adults with unresectable, locally advanced or metastatic disease,Advanced renal cell carcinoma after failure of sunitinib or sorafenib,Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in patients requiring therapeutic intervention but not candidates for curative surgery,Renal angiomyolipoma associated with TSC, not requiring immediate surgery,TSC-associated partial-onset seizures
Prevention of pregnancy
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Primarily metabolized by CYP3A4; also a substrate of P-glycoprotein (P-gp). Major metabolites include hydroxylated and demethylated products, with the parent compound being the main active moiety in plasma.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Approximately 92% bound to serum albumin and alpha-1-acid glycoprotein.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral bioavailability is 65-80% (first-pass metabolism); intravenous is 100%.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
GFR 30-89 m L/min: 1.5 mg/kg every 24 hours; GFR <30 m L/min: 1.5 mg/kg every 48 hours.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh Class B: 1 mg/kg every 12 hours; Child-Pugh Class C: 0.5 mg/kg every 12 hours.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Children (≥2 years): 1.5 mg/kg intravenously every 12 hours for 14 days; maximum 2 g/day.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific dose adjustment; monitor renal function and reduce dose if GFR <90 m L/min.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
None.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Non-infectious pneumonitis: Monitor for respiratory symptoms; manage with dose reduction or interruption.,Infections: Increased risk of bacterial, viral, fungal, and protozoal infections; monitor for signs and symptoms.,Oral ulceration: Manage with topical treatments, dose reduction, or interruption.,Renal failure: Monitor renal function; dose adjustment may be needed.,Metabolic effects: Monitor blood glucose and lipids; hyperglycemia, hyperlipidemia, and hypertriglyceridemia may occur.,Myelosuppression: Monitor blood counts; anemia, leukopenia, thrombocytopenia, and lymphopenia can occur.,Immunizations: Avoid live vaccines during treatment.,Embryo-fetal toxicity: Can cause fetal harm; advise women of reproductive potential of effective contraception.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Severe hypersensitivity to everolimus, other rapamycin derivatives, or any component of the formulation.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice, as they may inhibit CYP3A4 metabolism and increase MIUDELLA plasma concentrations. No other specific food restrictions; however, limit caffeine intake as it may exacerbate side effects like insomnia or anxiety.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second/third trimester: Increased risk of spontaneous abortion, intrauterine growth restriction, and oligohydramnios. Contraindicated in pregnancy.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Contraindicated due to potential toxicity; no human M/P ratio available. Excretion into breast milk is likely based on animal studies; discontinue nursing or drug.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Not applicable; contraindicated in pregnancy. No dose adjustment can mitigate teratogenic risk.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
MIUDELLA (fictitious drug) is a selective serotonin reuptake inhibitor (SSRI) indicated for major depressive disorder. Onset of therapeutic effect may require 2-4 weeks; assess suicide risk in young adults during initial therapy. Use with caution in patients with hepatic impairment (reduce dose by 50% for Child-Pugh class B/C). Avoid abrupt discontinuation to prevent withdrawal syndrome (taper over 2-4 weeks).
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take MIUDELLA exactly as prescribed at the same time each day, with or without food.,Do not stop taking MIUDELLA suddenly; a gradual dose reduction is required to avoid withdrawal symptoms.,Report worsening depression or suicidal thoughts immediately, especially during the first few months of treatment.,Avoid alcohol consumption while on MIUDELLA as it may increase drowsiness and potentiate central nervous system effects.,Contact your healthcare provider if you experience a rash, hives, or swelling, as these may indicate an allergic reaction.,Inform all healthcare providers that you are taking MIUDELLA, including before any surgery or dental procedure.,Store MIUDELLA at room temperature away from moisture and heat, and keep out of reach of children.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIUDELLA vs ALYACEN 1/35, answered by our medical review team.
MIUDELLA is a Oral Contraceptive that works by MIUDELLA (everolimus) is an m TOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the m TOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIUDELLA and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIUDELLA is: Intravenous: 1.5 mg/kg every 12 hours for 14 days.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIUDELLA and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIUDELLA is classified as Category C. Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second/third trimester. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.